Objective: The prevalence of coronary artery disease (CAD) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) remains unknown. We aimed to clarify the prevalence of CAD in patients with ATTR-CM and determine their clinical characteristics.
Method: In this single-center retrospective cross-sectional study, we retrieved the electronic medical records of patients diagnosed with ATTR-CM who were admitted between April 1992 and July 2023. Patients with ATTR-CM were identified using the International Classification of Diseases tenth revision (ICD-10) diagnosis and classified into 3 categories: (1) definite, (2) probable, and (3) possible, based on clinical data including endomyocardial biopsy,
99mTc-PYP scintigraphy, and cardiac magnetic resonance imaging. Cardiac catheterization data and a history of percutaneous coronary intervention (PCI) were reviewed.
Results: Among 80 patients diagnosed with ATTR-CM, 42 underwent a CAD work-up. Of these, 18 (43%) were identified as having CAD. Overall, high-sensitivity troponin I and BNP levels in the chronic phase were 154.5 (80.0–253.1) pg/mL and 446.9 (240.0–719.4) pg/mL, respectively. There were no significant differences in clinical characteristics between the CAD and non-CAD groups. Sixteen patients underwent PCI, and 6 patients were treated for acute coronary syndrome. Comorbidities included atrial fibrillation (n = 12, 67%), a history of hospitalization for heart failure (n = 8, 44%), and bradycardia requiring pacemaker treatment (n = 6, 33%). One patient died in the hospital after PCI.
Conclusions: The presence of CAD may be overlooked in patients with ATTR-CM owing to multiple comorbidities. Clinicians should be aware that CAD may be present in patients with ATTR-CM, similar to the general population.
View full abstract